Advertisement

Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp6, des-Gly-NH210]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience

  • Fernand Labrie
  • André Dupont
  • Alain Bélanger
  • Jacques Simard
  • Claude Labrie
  • Richard Poulin
  • Isabel Luthy
  • Raymonde Veilleux
  • Daniel Lacoste
  • Bianca Marchetti
  • Lionel Cusan
  • Gilles Manhès
  • Gérard Monfette
  • Jean Emond
Part of the Biochemical Endocrinology book series (BIOEND)

Abstract

Man is unique among species in having adrenals which secrete large amounts of precursor steroids which are converted into active androgens in the prostate and other peripheral tissues (Acevedo and Goldzieher, 1965; Harper et al., 1974; Cameron et al., 1966; Voigt and Bartsch, 1986).

Keywords

Androgen Receptor Medroxyprogesterone Acetate Cyproterone Acetate LHRH Agonist Adrenal Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acevedo, H.F., and Goldzieher, J.W., 1965, Further studies on the metabolism of 4-[4–14C]androstene-3,17-dione by normal and pathological human prostate tissue. Biochim. Biophys. Acta, 97:564.Google Scholar
  2. Bartsch, W., Knabbe, M., and Voigt, K.D., 1983, Regulation and compart-mentalization of androgens in rat prostate and muscle. J. Steroid Biochem., 19:929.PubMedCrossRefGoogle Scholar
  3. Baulieu, E.E., 1963, Studies on the secretion and interconversion of the androgens. Rec. Progr. Horm. Res., 19:306.Google Scholar
  4. Bélanger, A., Dupont, A., and Labrie, F. 1984, Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422.Google Scholar
  5. Brendler, H., 1959, Current Cancer Concepts: therapy with orchiectomy or estrogens or both. JAMA, 210:1074.CrossRefGoogle Scholar
  6. Cameron, E.H., Baillie, A.H., Grant, J.K., Milne, J.A., and Thomson, J., 1966, Transformation in vitro of [7α -3H]dehydroepiandrosterone to [3H]testosterone by skin from men. Proc. of the Society for Endocrinology, J. Endocrinol. 35:xix.Google Scholar
  7. Cupps, R.E., Utz, D.C., Fleming, T.R., Carson, C.C., Bastable, J.R.G., Glashan, R.W., Bouffioux, C., Lardennois, B., Williams, R.E., De Pauw, M., and Sylvester, R., 1980, Definitive radiation therapy for prostatic carcinoma: Mayo Clinic Experience. J. Urol., 124:855.Google Scholar
  8. Drouin, J., and Labrie, F., 1976, Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology, 98:1528.PubMedCrossRefGoogle Scholar
  9. Gibbons, R.P., Mason, J.T., Correa, R.A. Jr., Cummings, K.B., Taylor, W.J., Hafermann, M.D., and Richardson, R.D., 1979, Carcinoma of the prostate: local control with external beam radiation therapy. J. Urol., 121:310.PubMedGoogle Scholar
  10. Glashan, R.W., and Robinson, M.R.G., 1981, Cardiovascular complications in the treatment of prostatic carcinoma. Brit. J. Urol., 53:624.Google Scholar
  11. Harper, M.E., Pike, A., Peeling, W.B., and Griffiths, K., 1974, Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J. Endocrinol., 60:117.PubMedCrossRefGoogle Scholar
  12. Huggins, C., and Hodges, C.V., 1941, Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1:293.Google Scholar
  13. Johansson, J.E., Andersson, S.O., Beckman, K.W., Lingardh, G., and Zador, G., 1987, Clinical evaluation of Flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Urology, 29:55.PubMedCrossRefGoogle Scholar
  14. Johnson, D.E., Scott, W.W., Gibbons, R.P., Prout, G.R., Schmidt, J.D., Chu, T.M., Gaeta, J., Sarott, J., and Murphy, G.P., 1977, National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report. Cancer Treat. Rep., 61:317.Google Scholar
  15. Jordan, W.P. Jr., Blackard, C.E., and Byar, D.P., 1977, Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med. J.. 70:1411.Google Scholar
  16. Kaplan, E.L., and Meier, P., 1958, Non parametric estimation from incomplete observation. Amer. Statist. Assoc. J., 457.Google Scholar
  17. Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F., 1987, Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer. J. Ster. Biochem., 28: 379–384.Google Scholar
  18. Labrie, F., Auclair, C., Cusan, L., Kelly, P.A., Pelletier, G., and Ferland, L., 1978, Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. in: “Endocrine approach to Male Contraception”, Int. J. Androl, V. Hansson, ed., (suppl 2), p. 303.Google Scholar
  19. Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P.A., Lefebvre, F.A., Lemay, A., and Raynaud, J.P., 1980, Antifertility effects of LHRH agonists in the male. J. Androl., 1:209.Google Scholar
  20. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourcière, Y., Monfette, G., Laberge, J.G., Emond, J.P., Fazekas, A.T.A., Raynaud, J.P. and Husson, J.M., 1982, New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med., 5:267.Google Scholar
  21. Labrie, F., Dupont, A., and Bélanger, A., 1985a, A Complete androgen blockade for the treatment of prostate cancer, in: “Important Advances in Oncology”, V.T. De Vita, S. Hellman and S.A. Rosenberg, eds., J.B. Lippincott, Philadelphia.Google Scholar
  22. Labrie, F., Dupont, A., Bélanger, A., Lachance, R., and Giguère, M., 1985b, Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Brit. Med. J., 292:369.Google Scholar
  23. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., and Bergeron, V., 1985c, Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Ster. Biochem., 23:833.Google Scholar
  24. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., and Monfette, G., 1986, Treatment of prostate cancer with gonadotropin-releasing hormone agonists, Endocr Rev., 7:67.PubMedCrossRefGoogle Scholar
  25. Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., and A. Dupont, 1987a, New Concepts on the androgen sensitivity of prostate cancer, in: “Progress in Clinical and Biological Research”, Prostate Cancer, Part A: Research, Endocrine Treatment and Histopatholo-gy, G.P. Murphy, S. Khoury, C. Kuss, R. Châtelain and L. Denis, eds., vol. 243A, pp. 145–172.Google Scholar
  26. Labrie, F., Dupont, A., and Bélanger, A., 1987b, LHRH agonists and antiandrogens in prostate cancer, in: “Genitourinary Cancer”, T.L. Ratliff and W.J. Catalona, eds., pp. 157–200, Martinus Nijhoff Publishers, Boston.CrossRefGoogle Scholar
  27. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., and Bergeron, N., 1988, Benefits of combination therapy with Flutamide in patients relapsing after castration. Brit. J. Urol., 61:(in press).Google Scholar
  28. Labrie, F., and Veilleux, R., 1986, A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. The Prostate. 8:293.PubMedCrossRefGoogle Scholar
  29. Luthy, I., and Labrie, F., 1987, Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. The Prostate, 10:89.PubMedCrossRefGoogle Scholar
  30. Mettlin, C., Natarajan, N., and Murphy, G.P., 1982, Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int. Adv. Surg. Oncol., 5:277.Google Scholar
  31. Mobbs, B.G., Johnson, I.E., Connolly, J.G., and Thompson, J., 1983, Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J. Steroid Biochem., 19:1279.PubMedCrossRefGoogle Scholar
  32. Moguilewsky, M., Fiet, J., Tournemine, C., and Raynaud, J. P., 1986, Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cáncer. J. Steroid Biochem., 24:139.Google Scholar
  33. Moore, R.J., Gazak, J.M. and Wilson, R., 1984, Regulation of cytopolasmic dihydrotestosterone binding in dog prostate by 17ß-estradiol. J. Clin. Invest., 60:351.Google Scholar
  34. Murphy, G.P., Beckley, S., Brady, M.F., Chu, M., Dekernion, J.B., Dhabuwala, C., Gaeta, J.F., Gibbons, R.P., Loening, S.A., McKiel, C.F., McLeod, D.G., Pontes, J.E., Prout, G.R., Scardino, P.T., Schlegel, J.U., Schmidt, J.D., Scott, W.W., Slack, N.H., and Soloway, M., 1983, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormone alone. Cancer, 51:1264.PubMedCrossRefGoogle Scholar
  35. Nesbit, R.M., and Baum, W.C., 1950, Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA, 143:1317.CrossRefGoogle Scholar
  36. Ojasso, T., 1987, Nilutamide. Drugs of the Future, 12:763.Google Scholar
  37. Paulson, D.F., 1984, Treatment of locally confined prostatic cancer: radiotherapy versus surgery-limits of curability, in: “Progress and controversies in Oncological Urology”, K.I.H. Kurth, F.M.J. Debryene, F.H. Schraeder, T.A.W. Splinter and T.D.J. Wagener, eds, p. 482. Alan R. Liss Inc., New York.Google Scholar
  38. Pavone-Macaluso, M., De Voogt, H.J., Viggiano, G., Baqrasolo, E., Lardennois, B., De Pauw, M. and Sylvester, R., 1986, Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol., 136:624PubMedGoogle Scholar
  39. Poyet, P., Labrie, F., 1985, Comparison of the antiandrogenic/androgenic activities of Flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42: 283–288.Google Scholar
  40. Priore, R., 1984, Prognostic factors in NPCP protocols, in: “National Prostatic Cancer Project, Treatment Subgroup Meeting”, Minutes, New Orleans.Google Scholar
  41. Sanford, E.J., Paulson, D.F., Rohner, T.J., Drago, J.R., Santen, R.G., and Bardin, C.W., 1977, The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J. Urol., 118:1019.PubMedGoogle Scholar
  42. Simard, J., Luthy, I., Guay, J., Bélanger, A. and Labrie, F., 1986, Characteristics of interaction of the antiandrogen flutamide with the androgenr eceptor in various target tissues. Mol. Cell. Endocrinol., 44:261.Google Scholar
  43. Slack, N.H., Brady, M.F., Murphy, G.P (1984). Investigators in the National Prostatic Cancer Project Stable versus partial response in advanced prostate cancer, The Prostate, 4:401.CrossRefGoogle Scholar
  44. Smith, J.A., Glode, L.M., Wettlaufer, J.N., Stein, B.S., Glass, A.G., Max, T.D., Anbar, D., Jagst, C.L. and Murphy, G.P., 1985, Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of the prostate, Urology, 20:106.CrossRefGoogle Scholar
  45. Smith, Ph.D., Suciu, S., Robinson, M.R.G., Richards, B., Bastable, J.R.G., Glashan, R.W., Bouffioux, G., Lardennois, B., Williams, R.E., De Pauw, M. and Sylverter, R., 1986, A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J. Urol., 136:619.PubMedGoogle Scholar
  46. Sogani, P.C., Ray, B. and Whitmore, W.F. Jr., 1975, Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology, 6:164.PubMedCrossRefGoogle Scholar
  47. The Leuprolide Study Group, 1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl. J. Med., 311:1281.CrossRefGoogle Scholar
  48. Tomlinson, R.L., Currie, D.P. and Boyce, W.H., 1977, Radical prostatectomy: palliation for stage C carcinoma of the prostate. J. Urol., 117:85.PubMedGoogle Scholar
  49. Veterans Administration Cooperative Urological Research Group, 1967, Carcinoma of the prostate: treatment comparisons. J. Urol. 98: 516.Google Scholar
  50. Voigt K.D, Bartsch W., 1986, Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J. Steroid Biochem., 25:749.PubMedCrossRefGoogle Scholar
  51. Whitmore, W.F. Jr., 1973, The natural history of prostatic cancer. Cancer, 32:1104.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Fernand Labrie
    • 1
  • André Dupont
    • 1
  • Alain Bélanger
    • 1
  • Jacques Simard
    • 1
  • Claude Labrie
    • 1
  • Richard Poulin
    • 1
  • Isabel Luthy
    • 1
  • Raymonde Veilleux
  • Daniel Lacoste
    • 1
  • Bianca Marchetti
    • 1
  • Lionel Cusan
    • 1
  • Gilles Manhès
    • 1
  • Gérard Monfette
    • 1
  • Jean Emond
    • 1
  1. 1.Departments of Molecular Endocrinology, Medicine, Nuclear Medicine and UrologyLaval University Medical CenterCanada

Personalised recommendations